Search Result

Search Result

Results for "

cutaneous T-cell lymphoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) Autophagy (2) CCR (1) HDAC (1) HIV (2) Nucleoside Antimetabolite/Analog (2) RAR/RXR (2) TNF Receptor (1)
By Research Areas:	Cancer (8) Infection (2) Inflammation/Immunology (5)

8

Inhibitors & Agonists

3

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Targets Recommended: Anaplastic lymphoma kinase (ALK) BCL6 Itk TOPK MALT1 NAMPT ALCAM/CD166 GDNF Receptor Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Bexarotene 15+ Cited Publications LGD1069	RAR/RXR Autophagy	Cancer
Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC₅₀s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC₅₀ >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

Remetinostat SHP-141
Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma .

Bexarotene-d4 LGD1069 d₄	RAR/RXR Autophagy	Cancer
Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

Peldesine BCX 34	Nucleoside Antimetabolite/Analog HIV	Infection Inflammation/Immunology Cancer
Peldesine (BCX 34) is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC₅₀s of 36 nM, 5 nM, and 32 nM for *human, rat, and mouse red blood cell* (RBC) PNP, respectively. Peldesine is also a T-cell proliferation inhibitor with an IC₅₀** of 800 nM. Peldesine has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research .

Peldesine dihydrochloride BCX 34 dihydrochloride	Nucleoside Antimetabolite/Analog HIV	Infection Inflammation/Immunology Cancer
Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC₅₀s of 36 nM, 5 nM, and 32 nM for *human, rat, and mouse red blood cell* (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC₅₀** of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research .

HDAC6-IN-34	HDAC	Inflammation/Immunology
HDAC6-IN-34 (compound 21) is an oral active and selective HDAC6 inhibitor with the IC₅₀ of 18 nM. HDAC6-IN-34 increases the acetylation level of tubulin without affecting histone acetylation in cutaneous T-cell lymphoma cells and inhibits TNF-α secretion in LPS (HY-D1056)-stimulated macrophage cells. HDAC6-IN-34 shows excellent anti-arthritic efficacy in rat .

Brentuximab vedotin	Antibody-Drug Conjugates (ADCs) Apoptosis TNF Receptor	Cancer
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC₅₀ of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma .

Cat. No.	Product Name	Target	Research Area

Lacutamab IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)	Inhibitory Antibodies	Cancer
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

Zanolimumab Anti-Human CD4 Recombinant Antibody	Inhibitory Antibodies	Inflammation/Immunology Cancer
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us